Format

Send to

Choose Destination
See comment in PubMed Commons below
Hum Vaccin Immunother. 2014;10(1):146-9. doi: 10.4161/hv.26200. Epub 2013 Aug 27.

Fatal varicella due to the vaccine-strain varicella-zoster virus.

Author information

1
National Center for Immunization and Respiratory Diseases; Centers for Disease Control and Prevention; Atlanta, GA USA.
2
Department of Pediatrics; New York Medical College; New York, NY USA.
3
National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; Atlanta, GA USA.
4
Bureau of Immunization; New York State Health Department; Albany, NY USA.

Abstract

We describe a death in a 15-mo-old girl who developed a varicella-like rash 20 d after varicella vaccination that lasted for 2 mo despite acyclovir treatment. The rash was confirmed to be due to vaccine-strain varicella-zoster virus (VZV). This is the first case of fatal varicella due to vaccine-strain VZV reported from the United States. The patient developed severe respiratory complications that worsened with each new crop of varicella lesions; vaccine-strain VZV was detected in the bronchial lavage specimen. Sepsis and multi-organ failure led to death. The patient did not have a previously diagnosed primary immune deficiency, but her failure to thrive and repeated hospitalizations early in life (starting at 5 mo) for presumed infections and respiratory compromise treated with corticosteroids were suggestive of a primary or acquired immune deficiency. Providers should monitor for adverse reactions after varicella vaccination. If severe adverse events develop, acyclovir should be administered as soon as possible. The possibility of acyclovir resistance and use of foscarnet should be considered if lesions do not improve after 10 d of treatment (or if they become atypical [e.g., verrucous]). Experience with use of varicella vaccine indicates that the vaccine has an excellent safety profile and that serious adverse events are very rare and mostly described in immunocompromised patients. The benefit of vaccination in preventing severe disease and mortality outweigh the low risk of severe events occurring after vaccination.

KEYWORDS:

VZV; acyclovir resistance; vaccine adverse event; vaccine-strain; varicella; varicella-zoster virus

PMID:
23982221
PMCID:
PMC4181020
DOI:
10.4161/hv.26200
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center